Gabapentinoids (antiepileptics)
ATC code: N03AX16 (Pregabalin)
Brand names
Lyrica, Lyrica CR
GABA analogue that, like gabapentin, binds the α2δ subunit of voltage-gated calcium channels in the CNS. Inhibits excitatory neurotransmitter release. Compared with gabapentin, pharmacokinetics are more linear — bioavailability 90 % regardless of dose, simplifying titration. Effects on neuropathic pain and anxiety are comparable to gabapentin at much lower doses. Controlled substance: Schedule V in the US (since 2005) and Schedule 3 in the UK (since 2019).
First line
First-line for neuropathic pain per NeuPSIG 2015 and IASP 2022. Used in diabetic polyneuropathy, post-herpetic neuralgia, and spinal pain. Start 75 mg twice daily; titrate to 150–300 mg twice daily. Max 600 mg/day. Onset 1–2 weeks – faster than .
First line
Pregabalin is -approved for fibromyalgia (one of three drugs with this indication, alongside duloxetine and milnacipran); in the EU the indication is not registered (the application failed), so in Spain it is off-label. Per 2017, the only strong-for recommendation in fibromyalgia is exercise; all pharmacotherapy, pregabalin included, is a weak-for adjunct for a specific profile (pain, sleep disturbance). The pain effect is modest (NNT about 8), with a more noticeable effect on sleep. Dose 150-450 mg/day. Risks: dependence and abuse, weight gain, dizziness.
Sources
Second line
In Europe, pregabalin is -approved for generalized anxiety disorder; not in the US. Per NG113, second-line after SSRI/SNRI failure. Dose 150–600 mg/day. Efficacy comparable to SSRIs with faster onset (1–2 weeks vs 4–6). Advantage: no sexual dysfunction. Disadvantage: dependence/abuse risk, weight gain.
Sources
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Pregabalin (Lyrica) is an antiepileptic drug prescribed for neuropathic pain, fibromyalgia, generalized anxiety disorder, and partial epilepsy. For stress, insomnia, or emotional tension outside these indications, pregabalin is dangerous. The drug is a controlled substance in the US (Schedule V), the UK (Schedule 3 since 2019), and Russia (prescription-only with special requirements since 2019) because of abuse and dependence potential. In patients with a history of substance use disorder, the risk of pregabalin dependence is significant. On black markets in Eastern Europe and the CIS, Lyrica is one of the most popular illicit drugs. Abrupt discontinuation causes a severe withdrawal syndrome: anxiety, insomnia, tachycardia, and sometimes seizures. If pregabalin was prescribed for stress or sleep, consider seeking a second opinion.
Sources
4 pairs found. Sorted from critical to minor.
Mechanism
Pregabalin acts via the α2δ subunit of calcium channels and depresses the central nervous system. Morphine suppresses the respiratory centre via μ-opioid receptors. Effects are additive.
Symptoms
Drowsiness, slowed breathing (rate below 12/min), cyanosis of lips. Severe cases include respiratory arrest. Older patients: fall risk.
Management
The combination is possible in neuropathic pain or palliative cancer pain with careful titration. Keep doses minimal, provide naloxone to the patient and family, monitor respiratory rate and saturation.
Mechanism
Similar to tramadol + gabapentin: additive CNS depression, seizure risk (tramadol lowers threshold). issued a 2019 warning about respiratory depression with opioid-gabapentinoid combinations.
Symptoms
Drowsiness, sedation, slowed breathing. Seizures (tramadol) and syncope from orthostatic hypotension are possible. Older patients: fall risk.
Management
The combination is possible in neuropathic pain. Keep doses minimal, start low. Warn the patient about drowsiness and ataxia. Older patients: enhanced fall monitoring. Alternative opioid for neuropathic pain: pure opioid agonist (morphine, oxycodone) without serotonergic activity.
Mechanism
Additive CNS depression via different mechanisms (GABAergic for alprazolam, α2δ calcium channel blockade for pregabalin). Sedation, ataxia, and fall risk amplify, especially in older patients.
Symptoms
Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Ataxia and fall risk are especially pronounced in older patients.
Management
On starting the combination, begin both at minimal doses. Avoid the combination in older patients — fall and fracture risk. In neuropathic pain and anxiety, alternative: low-dose amitriptyline with buspirone, or duloxetine with CBT. If unavoidable, give alprazolam only at bedtime.
Mechanism
Similar to amitriptyline plus gabapentin — additive CNS depression. The combination is widely used in neuropathic pain, especially when monotherapy is insufficient.
Symptoms
Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.
Management
For neuropathic pain, start both at minimum doses: amitriptyline 10 mg at bedtime, pregabalin 75 mg twice daily. Up-titrate every 1–2 weeks as tolerated. Avoid in older patients — fall risk. Alternatives: duloxetine with topicals.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
FDA categories were retired in 2015. Teratogenicity data are mixed — Nordic registry data did not confirm increased malformation risk, but earlier studies signaled concern. In pregnant patients with epilepsy or severe neuropathic pain, individualized decision-making applies. For anxiety in pregnancy, SSRIs are preferred.
Transfers into breast milk. Manufacturer label advises against breastfeeding. Per LactMed, use when necessary with infant monitoring for sedation and poor weight gain.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Pregabalin is evaluated for the following indications with varying evidence strength: Neuropathic pain (evidence tier A), Fibromyalgia (evidence tier B), Generalized anxiety disorder (evidence tier B). See the full indication matrix with dosing and citations above on this page.
Common side effects of Pregabalin (≥ 1 in 100): Sedation, drowsiness, Dizziness, Weight gain (5–10 kg over 6 months), Peripheral edema, Dry mouth, Euphoria (some patients welcome it, increasing abuse risk). See the Safety section for uncommon and serious reactions.
FDA category C. FDA categories were retired in 2015. Teratogenicity data are mixed — Nordic registry data did not confirm increased malformation risk, but earlier studies signaled concern. In pregnant patients with epilepsy or severe neuropathic pain, individualized decision-making applies. For anxiety in pregnancy, SSRIs are preferred.
Transfers into breast milk. Manufacturer label advises against breastfeeding. Per LactMed, use when necessary with infant monitoring for sedation and poor weight gain.
Pregabalin is contraindicated in: Hypersensitivity; Age under 18 (for most indications except pediatric epilepsy from age 4); Rare hereditary galactose intolerance. Full list in the Safety section.
pregabalin is a controlled substance with dependence and abuse risk. Use without a clinical diagnosis is unsafe.
pregabalin causes sedation, but as a side effect — not as an indication. For insomnia, drugs with better safety profiles exist (melatonin, short-course doxylamine, third-generation hypnotics on indication). Self-medicating insomnia with pregabalin is unjustified.